What to Expect at the Leading Industry Touchpoint for Drug-Diagnostic Co-Development
As the precision medicine field continues to evolve at lightning speed, from next generation ADCs and CGT drug-diagnostics to novel CNS and rare disease biomarkers, this year's milestone 15th World Clinical Biomarkers & Companion Diagnostics Summit is your chance to discover the latest clinical case studies, global regulatory shifts, and harmonized commercialization strategies shaping the future of personalized care.Â
Unmissable Agenda Highlights
Bolster Biomarker Discovery & Validation
Uncover cutting-edge progress in genomic sequencing, ctDNA, and MRD biomarkers, empowering earlier detection and real-time disease monitoring with BlossomHill Therapeutics and Genentech
Implement Novel Technologies & Trials
Charter the integration of omics and AI-driven biomarker strategies advancing early detection and personalized therapies across high-burden indications with Novartis, PrecisionLife and Takeda
Pioneer Digital & AI-Enabled Innovations
Discover the workflows, models and adoption strategies behind scalable and physician appropriate digital and computational pathology innovations with AstraZeneca, Friends of Cancer Research and Bayer
Optimize Drug-Diagnostic Co-Development
Explore the initiation, scale-up and regulatory responsibilities of co-development partnerships to spark compliant and scalable strategic alliances with GSK, Vertex Pharmaceuticals and Pfizer
Streamline CDx Development & Commercialization
Discover fit-for-purpose CDx strategies that mitigate testing disparities, reduce clinical setbacks, and strengthen therapeutic development with Alexion and Astellas Pharma
Navigate IVDR Adherence
Cast your attention to the expectations of global regulatory and notified bodies to streamline harmonized drug-diagnostic compliance and approvals worldwide with Eli Lilly, Daiichi Sankyo and Regeneron
Divide & Conquer
The precision medicine field is vast, which is why we have meticulously researched with subject matter experts to identify the key challenges facing the community across indications, biomarkers, biopsy types, testing technologies and drug modalities.
By splitting into 3 end-to-end tracks (Biomarker Discovery & Translational Development, Clinical Biomarker Development and CDx Development & Commercialization), our speakers have tailored their presentations to dive into specific challenges for those stages of development.
By sending different members of the team across the drug pipeline, you can be sure you’ve left no stone unturned and have a team inspired with actionable takeaways to apply to their work.
A snapshot of key sessions featured in each track across the 2025 program:
Biomarker Discovery & Translational Development
Pioneering Digital & Blood-Based Biomarkers for Early Detection & Tailored Therapies in Chronic & Neurological Diseases
- Simon Beaulah, Senior Vice President, Healthcare & Head of US Operations, PrecisionLife
- Ying Wu, Director & Head of Human Genetics, Eisai
Clinical Biomarker Development
Enhancing Biomarker-Driven Trial Execution for Patient-Centric & Enhanced Care Pathways
- Irina Leaf, Director, Therapeutic Area Biomarker Lead, Disease Area X & Global Health, Novartis
- Viktor Adalsteinsson, Director, Gerstner Center for Cancer Diagnostics, Broad Institute
CDx Development & Commercialization
Expanding Precision Medicine’s Reach: Driving Harmonized Commercialization of Drug-Diagnostics to Enable Timely, Adoptable Therapy Launch
- Dishant Kalra, Head of Precision Medicine, Astellas Pharma
- Ben Withey, Director, Commercial Diagnostics, CDx Lead, Pfizer
Explore the Full Event Guide
- Free* to Attend for Biopharma & Academia
- The World's Leading Biomarker & Drug-Diagnostic Forum
- Co-Development & Partnership Selection Panels
- Oncology, Neurological, Chronic, Autoimmune, & Rare Disease Biomarker Strategies
- Case studies on Genomic, Omic, Pathology, Flow Cytometry, & Cell Sequencing IVDs
- Exclusive Networking & Partnerships Opportunities
Attending Companies Include
Explore the Agenda
Hear the latest translational, clinical and post-approval breakthroughs and gain exclusive insights into precision medicine innovations during our packed agenda, interactive roundtables, and new drug-diagnostic partnerships panel discussions
Partner With Us
Position yourself alongside other leading IVD and CDx solution providers to ensure your brand is at the heart of precision medicines deals and collaborations
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning a range of precision therapy modalities and indications, and make critical connections during our dedicated networking sessions